Merck's Keytruda extends life for kidney cancer patients after surgery, while Bristol's Opdivo fails again
Fierce Pharma
JANUARY 26, 2024
Merck’s unique approval for Keytruda as a postsurgical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives. | Merck’s unique approval for Keytruda as a postsurgerical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives.
Let's personalize your content